Mirabella (Ethinylestradiol, Levonorgestrel | Lactose)

Ethinylestradiol, a synthetic estrogen, suppresses follicle‑stimulating hormone, while levonorgestrel, a synthetic progestogen, blocks the luteinizing hormone surge, preventing ovulation. Levonorgestrel also thickens cervical mucus and changes the endometrial lining, reducing the chance of fertilization and implantation.

The dosing regimen for Mirabella is determined by the prescribing healthcare professional. Typically, it is taken as one tablet daily at the same time each day, but the exact schedule and any missed‑dose instructions should follow the prescriber’s guidance.

Mirabella is contraindicated during pregnancy and should not be started if a woman is pregnant. While limited data exist for breastfeeding, most guidelines advise caution; women should discuss risks and benefits with their healthcare provider before using hormonal contraception while nursing.

To order Mirabella, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mirabella contains the widely used dose combination of ethinylestradiol and levonorgestrel, offering efficacy comparable to other combined oral contraceptives. Its safety profile and side‑effect spectrum are similar to alternative estrogen‑progestin pills, with differences mainly in individual tolerability and specific hormone doses.

Mirabella tablets should be stored at ambient temperature, below 25 °C, in the original blister pack to protect from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged.

Mirabella is taken orally, usually one tablet each day, preferably at the same time each day. It is part of a 21‑day active tablet regimen followed by a hormone‑free interval, but patients should follow the specific instructions provided by their prescriber.

Serious risks include venous thromboembolism, arterial thrombosis, hypertension, and severe allergic reactions. Women with a history of blood clots, smoking over age 35, uncontrolled hypertension, or liver disease should discuss these risks with their healthcare provider before starting Mirabella.

Mirabella should not be used by women who are pregnant, have a known or suspected pregnancy, have a history of thromboembolic disorders, active liver disease, uncontrolled hypertension, breast cancer, or who are over 35 and smoke regularly. Contraindications must be evaluated by a qualified prescriber.